Generic Azopt Availability
AZOPT (brinzolamide - suspension/drops;ophthalmic)
Manufacturer: ALCON PHARMS LTD
Approval date: April 1, 1998
Strength(s): 1% [RLD]
Has a generic version of Azopt been approved?
No. There is currently no therapeutically equivalent version of Azopt available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Azopt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Sulfonamides useful as carbonic anhydrase inhibitors
Issued: January 3, 1995
Inventor(s): Dean; Thomas R. & Chen; Hwang-Hsing & May; Jesse A.
Assignee(s): Alcon Laboratories, Inc.
Sulfonamides and pharmaceutical compositions containing the compounds useful in controlling intraocular pressure are disclosed. Methods for controlling intraocular pressure through administration of the compositions are also disclosed.Patent expiration dates:
- October 1, 2012✓
- October 1, 2012
Topical ophthalmic pharmaceutical vehicles
Issued: October 24, 1995
Inventor(s): Ali; Yusuf & Reed; Kenneth W.
Assignee(s): Alcon Laboratories, Inc.
Universal ophthalmic pharmaceutical vehicles which increase in viscosity upon instillation in the eye are disclosed. Ophthalmic compositions of the universal vehicle and a pharmaceutically active drug are also disclosed. In one embodiment, the vehicle gels upon instillation in the eye. In another embodiment, suspension vehicles having superior physical stability are provided.Patent expiration dates:
- October 24, 2012✓✓
- April 24, 2013✓
- October 24, 2012
- Azopt drops Consumer Information (Wolters Kluwer)
- Azopt Consumer Information (Cerner Multum)
- Azopt Advanced Consumer Information (Micromedex)
- Azopt 1% Advanced Consumer Information (Micromedex)
- Azopt AHFS DI Monographs (ASHP)
- Brinzolamide drops Consumer Information (Wolters Kluwer)
- Brinzolamide ophthalmic Consumer Information (Cerner Multum)
- Brinzolamide Ophthalmic Advanced Consumer Information (Micromedex)
- Brinzolamide AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|